Clinical Trials

10 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06806033 2026-03-31

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02436707 2026-03-27

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

129 enrolled

Lymphoma

NCT04960618 2026-03-23

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

14 enrolled

Mycosis Fungoides, Sezary Syndrome

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

40 enrolled

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Hodgkin Disease

NCT05502250 2026-03-06

HOVON164HL

75 enrolled

Hodgkin Disease

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

84 enrolled

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

43 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05508867 2026-01-20

MK-4280A-008

203 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT06905509 2025-09-29

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

25 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

180 enrolled

Lymphoma, B-Cell

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

56 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

71 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02750670 2025-06-22

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

30 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

130 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06601504 2025-06-06

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

61 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Hodgkin Disease

NCT06854445 2025-03-24

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

55 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03615664 2025-01-16

BURGUND

115 enrolled

Hodgkin Disease, Lymphoma

NCT02692248 2024-10-10

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

64 enrolled 17 charts

Lymphoma, Large B-Cell, Diffuse

NCT01626664 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

LymphoidOther hematologic neoplasm

71 enrolled 15 charts

Leukemia-Lymphoma, Adult T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04220008 2024-01-12

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00574496 2023-09-28

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

25 enrolled 10 charts

Hodgkin Disease, Lymphoma, Recurrence

NCT04022005 2023-09-11

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

54 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT00377052 2023-08-04

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

29 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01746173 2023-01-30

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

5 enrolled 7 charts

Lymphoma, T-Cell

NCT03422523 2022-08-22

ARGO

53 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03488251 2022-08-16

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

8 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

54 enrolled

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

54 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

15 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT00436280 2020-08-06

Chemotherapy for Participants With Lymphoma

68 enrolled 20 charts

Lymphoma, Large B-Cell, Diffuse

NCT04405375 2020-05-28

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

29 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

21 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT00014209 2020-04-09

Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment

77 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT02918747 2020-01-28

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

100 enrolled

Lymphoma

NCT03339700 2020-01-14

Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01200329 2019-12-16

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

81 enrolled 8 charts

Hodgkin Disease, Lymphoma, Recurrence

NCT00003397 2019-11-04

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma